Skip to Main Content
Health Science Information Consortium
LibGuides
The Regional Municipality of York
York Region COVID-19 Guidance
Treatment
Search this Guide
Search
York Region COVID-19 Guidance
An online repository of guidance documents relevant to COVID-19 for use of York Region Public Health
Home
Ontario Ministry Guidance
IOB resources
General
Acute Care
Assessment/Assessment Clinics
Communications
Community Care / Transmission
Toggle Dropdown
Pharmacies
COVID-19 Variants
Dental Care
Diagnosis
Epidemiology
Toggle Dropdown
Surveillance
Transmission
Forecasting
Seasonality
Ethics
Farms & Migrant Workers
Food Premises
Toggle Dropdown
Food Safety
Health Care Workers
Health Emergency Planning
Toggle Dropdown
Paramedics
Home Care
Infodemics
IPAC Measures
Toggle Dropdown
PPE
Infection Control
Disinfection
Face Masks
Laboratories
Toggle Dropdown
Testing and Results Specifications
Long Covid
Long Term Care Homes
Mass Gatherings
Toggle Dropdown
Religious Services
Mental Health
Palliative Care
Pets
Post Exposure
Toggle Dropdown
Self-Monitoring
Quarantine
Post-Pandemic Planning
Postmortem Guidance
Prisons
Public Health
Schools
Toggle Dropdown
Childcare
Postsecondary
Treatment
Vaccination Planning
Vaccine Safety
Vulnerable Populations
Toggle Dropdown
Addictions
Children
Chronic Conditions
Health Equity
Homelessness
ImmunoCompromised Conditions
Pregnancy
Seniors
Women
Water and Wastewater
Workplaces
CANADIAN
Government of Canada
Details for: PAXLOVID - COVID-19 [Last update Jan 2022]
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels [Jan 17 2022]
Regulatory Decision Summary - Paxlovid - Health Canada [Dec 1 2021]
Public Health Ontario
SYNOPSIS COVID-19 What We Know So Far About… Use of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) [PHO, Apr 3, 2020]
Other
Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant [PHAC Jan 7 2022]
Evidence-Based Recommendations on the Use of Casirivimab + Imdevimab, and Sotrovimab for Adults in Ontario [Science Table Sept 30 2021]
Fluvoxamine: What Prescribers and Pharmacists Need to Know [Science Table Jan 12 2022]
Fluvoxamine for symptomatic outpatients with COVID-19 [CMAJ Jan 2022]
Ivermectin Evidence Review Update [AHS Scientific Advisory Group Oct 5 2021]
Nirmatrelvir/ Ritonavir (Paxlovid) : What prescribers and Pharmacists Need to Know [Science Table Jan 25 2022]
PRODUCT MONOGRAPH : PAXLOVID [Pfizer Jan 17 2022]
Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial [CMAJ Jan 2022]
Science Briefs: Baricitinib for Hospitalized Patients with COVID-19 [Science Table V 1.0 Jan 8 2022]
Science Briefs: Heparin Anticoagulation for Hospitalized Patients with COVID-19 [Science Table, Covid-19 Advisory for Ontario Sep 3 2021]
Therapeutic Management of Adult Patients with COVID-19 [Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group V11 Apr 1 2022]
Treatment of COVID-19 with PAXLOVID [CPhA Jan 5 2022]
Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline [CMAJ May 2020]
CADTH. Ongoing trials for drugs in the prevention and treatment of COVID-19 [Apr 2021]
CADTH. Chloroquine and Hydroxychloroquine, With or Without Azithromycin, for COVID-19: A Brief Overview (Apr 20)
Prince Edward Island. Guidelines for the Management and Control of COVID-19 [Mar 2020]
Emerging Evidence on COVID-19: Evidence Brief of Ivermectin [PHAC 2021 Jun 23]
INTERNATIONAL
Centers for Disease Control and Prevention (CDC)
What Clinicians Need to Know About the New Oral Antiviral Medications for COVID-19 [Jan 12 2022]
European Centre for Disease Control (ECDC)
Public Health England
World Health Organization
Clinical Management of COVID-19: CASIRIVIMAB AND IMDEVIMAB FOR COVID-19
A living WHO guideline on drugs for covid-19 [last update Jan 13 2022]
Therapeutics and COVID-19: living guideline, 14 January 2022
WHO R&D Blueprint, novel Coronavirus: Good participatory practice for COVID-19 clinical trials: a toolbox
WHO R&D Blueprint novel Coronavirus: Core protocol for therapeutics against COVID19 (Apr 28)
Other
Assessment report : Use of molnupiravir for the treatment of COVID-19 [EMA Jan 27 2022]
CONDITIONS OF USE, CONDITIONS FOR DISTRIBUTION AND PATIENTS TARGETED AND CONDITIONS FOR SAFETY MONITORING ADDRESSED TO MEMBER STATES : Paxlovid
Covid-19: FDA expert panel recommends authorising molnupiravir but also voices concerns [BMJ Dec 2 2021]
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients [NEJM Jan 2022]
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant [NEJM Jan 2022]
FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR MOLNUPIRAVIR [FDA Dec 23 2021]
FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID [FDA Dec 2021]
In brief Sotrovimab [NSW COVID-10 Critical Intelligence Unit Jan 21 2022]
Memorandum Explaining Basis for Revocation of Emergency Use Authorization for Emergency Use of Chloroquine Phosphate and Hydroxychloroquine Sulfate [FDA Jun 15 2020]
Recommendations for Investigational COVID-19 Convalescent Plasma [FDA Jan 10 2022]
Remdesivir for the Treatment of Covid-19 — Final Report [NEJM Nov 5 2020]
Use of molnupiravir for the treatment of COVID-19 [EMA Nov 19 2021]
<<
Previous:
Postsecondary
Next:
Vaccination Planning >>